Nurix Therapeutics (NRIX)
NASDAQ:NRIX
Want to see NRIX full AI Analyst Report?
NRIX Stock Chart & Stats
$17.51
$0.42(2.22%)
At close: 4:00 PM EST
$17.51
$0.42(2.22%)
Day’s Range― - ―
52-Week Range$8.20 - $22.50
Previous CloseN/A
Volume302.00K
Average Volume (3M)1.30M
Market Cap
$1.75B
Enterprise Value$1.45B
Total Cash (Recent Filing)$540.73M
Total Debt (Recent Filing)$58.66M
Price to Earnings (P/E)―
Beta1.49
Next Earnings
Jul 09, 2026EPS Estimate
-0.72Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.16
Shares Outstanding103,405,815
10 Day Avg. Volume1,346,574
30 Day Avg. Volume1,295,840
Financial Highlights & Ratios
PEG Ratio-0.94
Price to Book (P/B)2.72
Price to Sales (P/S)17.45
P/FCF Ratio-5.56
Enterprise Value/Market Cap0.83
Enterprise Value/Revenue20.27
Enterprise Value/Gross Profit-14.53
Enterprise Value/Ebitda-5.03
Forecast
1Y Price Target
$30.71Price Target Upside75.41% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-2.97
Revenue Forecast (FY)$56.43M
Bulls Say, Bears Say
Bulls Say
Cash Runway And Funding VisibilityA substantial cash balance supported by equity raises and collaboration milestones provides funding visibility to advance key clinical and development programs without immediate financing pressure.
Industry Partnerships And Program LicensingA prior collaboration with a major biopharma partner that included upfront payment and potential milestone and royalty payments serves as external validation and could attract further partnership interest.
Preclinical And Scientific ValidationAcceptance of multiple oral and poster presentations and strong preclinical tumor control data for degrader programs provide scientific validation that could increase investor confidence in the technology platform.
Bears Say
Clinical Proof-of-concept FailureNegative clinical proof-of-concept for any lead degrader candidate would materially undermine development plans and likely depress company valuation.
Collaboration Revenue ShortfallCollaboration revenue below expectations widened the accounting net loss and could pressure near-term financial results and investor sentiment.
Execution And Regulatory RiskReliance on multiple pivotal trials and sequential data readouts increases execution risk, making stock performance highly sensitive to trial outcomes and regulatory decisions.
Nurix Therapeutics News
NRIX FAQ
What was Nurix Therapeutics’s price range in the past 12 months?
Nurix Therapeutics lowest stock price was $8.20 and its highest was $22.50 in the past 12 months.
What is Nurix Therapeutics’s market cap?
Nurix Therapeutics’s market cap is $1.75B.
When is Nurix Therapeutics’s upcoming earnings report date?
Nurix Therapeutics’s upcoming earnings report date is Jul 09, 2026 which is in 65 days.
How were Nurix Therapeutics’s earnings last quarter?
Nurix Therapeutics released its earnings results on Apr 08, 2026. The company reported -$0.79 earnings per share for the quarter, missing the consensus estimate of -$0.763 by -$0.027.
Is Nurix Therapeutics overvalued?
According to Wall Street analysts Nurix Therapeutics’s price is currently Undervalued.
Does Nurix Therapeutics pay dividends?
Nurix Therapeutics does not currently pay dividends.
What is Nurix Therapeutics’s EPS estimate?
Nurix Therapeutics’s EPS estimate is -0.72.
How many shares outstanding does Nurix Therapeutics have?
Nurix Therapeutics has 103,405,815 shares outstanding.
What happened to Nurix Therapeutics’s price movement after its last earnings report?
Nurix Therapeutics reported an EPS of -$0.79 in its last earnings report, missing expectations of -$0.763. Following the earnings report the stock price went down -4.587%.
Which hedge fund is a major shareholder of Nurix Therapeutics?
Currently, no hedge funds are holding shares in NRIX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Nurix Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$30.71 (75.41% Upside)
$30.71 (75.41% Upside)
Blogger Sentiment
Bullish
NRIX Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 3.7M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.8%
Last 30 Days ▲ 19.8%
Last 30 Days ▲ 19.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
70.99%
12-Months-Change
Fundamentals
Return on Equity
-64.21%
Trailing 12-Months
Asset Growth
3.43%
Trailing 12-Months
Company Description
Nurix Therapeutics
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; and DeTIL-0255 that is in the Phase 1 clinical trial for the treatment of gynecologic cancers, including ovarian, endometrial, and cervical cancer. The company has a strategic collaboration agreement with Gilead Sciences, Inc. for cancer and other challenging diseases patients; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.
NRIX Stock 12 Month Forecast
Average Price Target
$30.71
▲(75.41% Upside)
Technical Analysis
Arvinas Holding Company
―
Vir Biotechnology
―
Relay Therapeutics
―
Terns Pharmaceuticals
―
Ownership Overview
0.19% Insiders
16.22% Mutual Funds
2.73% Other Institutional Investors
57.85% Public Companies and
Individual Investors